Cancer vax developer Kite lands $15M

 

LA-based Kite Pharma, a fledgling biotech that has set out to develop new cancer vaccine therapies, has raised $15 million in Series A venture cash. The company will use the funding to support development of its preclinical pipeline and work on its Phase I therapeutic vaccine for hepatocellular cancer. Kite release

Suggested Articles

Manufacturing

Daiichi Sankyo comes up far short in avian flu vaccine effort

Daiichi Sankyo says it still unable to fulfill a government mandate to be able to produce enough H5N1 flu vaccine to fight an epidemic in Japan.

by Eric Palmer
shingrix
Pharma Asia

GSK's booming Shingrix wins nod to tackle China

GSK’s Shingrix has continuously impressed industry watchers with its growth, and the company just added another large market to its list: China.

by Angus Liu
WuXi Biologics Shanghai innovation center
Manufacturing

WuXi to build vaccine plant in deal it values at $3B

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a $3 billion contract.

by Eric Palmer